Kovai Medical Center & Hospital Ltd Q2 FY26 – The Doctor From Coimbatore Who Runs a ₹6,772 Cr Enterprise Like a Startup Surgeon with a Scalpel (and a Spreadsheet)
1. At a Glance
Kovai Medical Center & Hospital Ltd (KMCH), the Coimbatore-born healthcare empire that decided curing people wasn’t enough, so it added teaching them too. Trading at ₹6,190 with a market cap of ₹6,772 crore, the company is that rare South Indian blend of clinical precision and business aggression. In Q2 FY26, KMCH clocked quarterly sales of ₹392 crore (up 14% YoY) and a PAT of ₹58.9 crore (up 16% YoY). The hospital chain now runs on a 28% operating profit margin, which is about as healthy as the patients leaving their cardio ward.
With ROE at a fabulous 21.2% and ROCE at 23.3%, the numbers scream efficiency. Debt? Down to ₹399 crore from ₹550 crore two years ago—some hospitals reduce cholesterol, KMCH reduces leverage. Meanwhile, the stock has delivered 55% returns over three years, proving once again that Coimbatore engineers don’t just make motors; they make multi-bagger hospitals.
The company’s shiny new move: buying land in Chennai worth ₹121 crore to build a new hospital. From phosgene plants in Gujarat to biotech startups in Hyderabad, everyone’s diversifying. KMCH just joined that elite club—only it diversified from hearts to hearts and minds by adding a medical college.
2. Introduction
Welcome to Kovai Medical Center & Hospital Ltd, where Tamil efficiency meets Western healthcare standards. It started as a single hospital and grew into a ₹1,478 crore revenue machine that heals bodies, prints profits, and now, teaches future doctors how to do both.
Every investor knows Apollo Hospitals and Max Healthcare—but KMCH is that quiet Coimbatore cousin who doesn’t attend family functions but somehow builds a bungalow bigger than everyone else’s.
The company’s two major arteries: healthcare (94% of H1 FY25 revenue) and education (6%). The first one saves lives; the second one charges ₹14 lakh per seat to teach how to save them. The KMCH Institute of Health Sciences & Research, launched in 2019, now operates at full capacity with 750 seats and the kind of technology that would make even AIIMS blush—CT, MRI, CATH labs, and AI-assisted robots that sound like something Elon Musk might have suggested over filter coffee.
What’s impressive? Between FY22 and FY24, healthcare revenue grew 28%, but education revenue exploded 228%. If that’s not a turnaround, it’s a syllabus change.
Bed occupancy rates climbed from 48.7% to 60.8% in two years. Inpatient count jumped 35%. Outpatients? Up 47%. Average stay length dropped slightly—patients are healing faster, or maybe rooms are needed for the next batch. Either way, efficiency looks as sharp as a surgeon’s scalpel.
3. Business Model – WTF Do They Even Do?
Let’s simplify the KMCH model. Step 1: Open a hospital. Step 2: Treat patients with cutting-edge tech. Step 3: Make money from teaching the next generation how to do Step 2. Repeat, scale, and sprinkle a bit of robotic surgery drama.
The healthcare segment is the main engine—2,250 beds across Coimbatore, Sulur, Erode, and Kovilpalayam. KMCH is a regional healthcare fortress in Tamil Nadu. It dominates oncology and cardiology with precision programs in pediatric, head & neck, and cardio-oncology. Think of it as the Marvel Cinematic Universe of medical departments—each specialty strong enough to stand alone, but together, they form “The Avengers of Kovai.”
Then comes education—the KMCH Institute of Health Sciences & Research. 750 seats, 40 ICU beds, 14 operation theatres, and an army of students who pay ₹14 lakh each per year. That’s ₹105 crore of annual tuition right there. And because the hospital and college are symbiotic, the college trains the doctors who later work at the hospital—a literal pipeline of profitability.
It’s the perfect loop: the hospital funds the college, the college trains doctors, doctors return to the hospital, and the hospital funds the next hospital. Corporate reincarnation at its finest.
4. Financials Overview
Metric
Latest Qtr (Sep FY26)
YoY Qtr (Sep FY25)
Prev Qtr (Jun FY26)
YoY %
QoQ %
Revenue
₹392 Cr
₹344 Cr
₹374 Cr
13.9%
4.8%
EBITDA
₹107 Cr
₹96 Cr
₹106 Cr
11.5%
0.9%
PAT
₹58.9 Cr
₹51.0 Cr
₹57.0 Cr
15.5%
3.3%
EPS (₹)
53.8
46.3
52.3
16.2%
2.9%
Annualised EPS = 53.8 × 4 = ₹215.2 At CMP ₹6,190, that gives a P/E of ~28.8x — remarkably disciplined for a hospital stock when peers like Fortis or Max are flaunting 80–90x.
Commentary: KMCH isn’t shouting for attention—it’s performing silent surgery on its balance sheet. Margins are stable, profit is growing, and the QoQ rise looks consistent. This is the kind of boring growth that makes portfolio managers smile and traders yawn—until it doubles.
5. Valuation Discussion – Fair Value Range (Educational Only)
If KMCH trades at 35x P/E (reasonable for steady growth), fair value = 35 × 209 = ₹7,315/share. If it trades at 25x P/E (conservative), fair value = 25 × 209 = ₹5,225/share. Range: ₹5,225 – ₹7,315
Method 2: EV/EBITDA Method EV = ₹6,863 Cr; EBITDA (FY25) = ₹417 Cr Current EV/EBITDA = 16.4x If valued between 14–18x → Fair EV = ₹5,838 – ₹7,506 Cr Subtract net debt (₹399 Cr): Fair market cap = ₹5,439 – ₹7,107 Cr Per share (1.09 Cr shares): ₹4,990 – ₹6,520/share
Method 3: DCF (Simplified) Assume 13% CAGR in free cash flow for 5 years, 9% cost of capital, 2% terminal growth. Estimated fair range: ₹5,800 – ₹6,600/share
🩺 Educational Fair Value Range: ₹5,200 – ₹7,300/share. (For education only. Not investment advice. No scalpels or SEBI violations here.)
6. What’s Cooking – News, Triggers, Drama
KMCH doesn’t thrive on drama but still finds some. In October 2025, the Tamil Nadu Consumer Commission fined them ₹15 lakh for compensation. Company’s response? “We’ll appeal.” That’s the corporate equivalent of “Talk to my lawyer.”
In August 2024, they spent ₹121 crore acquiring 1.28 acres in Chennai. Translation: “Coimbatore is
